

Robert Greene Sterne Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael G. Lee John M. Covert Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Jeffrey T. Helvey Eldora L. Ellison Donald R. Banowit

Bian J. Del Buono
Mark Fox Evens
Vincent L. Capuano
Elizabeth J. Haanes
Michael D. Specht
Kevin W. McCabe
Glenn J. Perry
Edward W. Yee
Grant E. Reed
Virgil Lee Beaston
Theodore A. Wood
Joseph S. Ostroff
Jason D. Eisenber
Jiracy L. Muller
Jon E. Wright
Ann E. Summerfield
Ann E. Summerfleld
Alelene C. Carfson

Cyntina M. Boutler Gaby L. Longsworth Lori A. Gordon Laura A. Vogel Bryan S. Wade Bashir M.S. Ali Shannon A. Carroll Arbar F. Khal Michelle K. Holoubek Marsha A. Rose Scott A. Schaller Lei Zhou Young Tang Christopher J. Walsh W. Blake Coblentz-James J. Pohl John T. Haran Mark W. Rygiel Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Siever*
Ulrike Winkler
Bryan L. Skelton*
Paul A. Calvo
Robert A. Schwartzman
C. Matthew Rozier
Alexandra K. Pechhold
Registered Patent Agent

Registered Patent Agents • Karen R. Markowicz Matthew J. Dowd Katrina Yujian Pei Quach Julle A. Heider Mita Mukherjee Scott M. Woodhouse Peter A. Socarras Jeffrey K. Mills Danielle L. Letting Lori Brandes Steven C. Oppenheimer Aaron S. Lukas Gaurav Asthana

Of Counse) Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie Christopher P. Wrist

*Admitted only in Maryland
*Admitted only in Virginia
•Practice Limited to

July 13, 2007

WRITER'S DIRECT NUMBER: (202) 772-8560 INTERNET ADDRESS: RESMOND@SKGF.COM

Art Unit 1614

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/572,910; Filed: March 21, 2006

For: Substituted 2-Arylmethylene-N-aryl-N'-aryl-malonamides and Analogs as Activators of Caspases and Inducers of Apoptosis

Inventors: CAI et al.

Our Ref: 1735.0930001/RWE/BSA

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Executed Statement Under 37 C.F.R. 3.73(b);
- 2. Executed Power of Attorney from Assignee; and
- 3. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond Attorney for Applicants Registration No. 32,893

RWE/BSA/nef Enclosures

691383 1.DOC

Sterne, Kessler, Goldstein & Fox Pllic.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skqf.com



PTO/SB/96 (09-0) Approved for use through 03/31/2007. OMB 0651-003 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number
STATEMENT UNDER 37 CFR 3.73(b) 1735.0930001/RWE/BSA
Applicant/Patent Owner: Cytovia, Inc.
Application No./Patent No.: 10/572,910 Filed/Issue Date: March 21, 2006
Entitled: Substituted 2-Arylmethylene-N-aryl-N'-aryl-malonamides and Analogs as Activators of Caspases and Inducers of Apoptosis
Cytovia, Inc , a <u>corporation</u>
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is: 1. X the assignee of the entire right, title, and interest; or
an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is%)
in the patent application/patent identified above by virtue of either:
A.X An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel <u>019320</u> , Frame <u>0313</u> , or for which a copy thereof is attached.
OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
1. From:To:To:
The document was recorded in the United States Patent and Trademark Office at Reel, or for which a copy thereof is attached.
2. From: To:
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
From:To:To:The document was recorded in the United States Patent and Trademark Office at
Reel, Frame, or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet.
X As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
Signature Signature Date SSENG SS
Printed or Typed Name Telephone Number
VP Research
Title

This collection of Information is required by 37 CFR 3.73(b). The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chlef Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

POWER OF ATTORNEY FROM ASSIGNEE

Cytovia, Inc, a corporation of Delaware, having a principal place of business at 6650 Nancy Ridge Drive, San Diego, California 92121, is assignee of the entire right, title, and interest for the United States of America (as defined in 35 U.S.C. §100), by reason of an Assignment to the Assignee executed on (1) February 10, 2006; (2) March 7, 2006; (3) February 13, 2006; (4) February 24, 2006, of an invention known as Substituted 2-Arylmethylene-Naryl-N'-aryl-malonamides and Analogs as Activators of Caspases and Inducers of Apoptosis (Attorney Docket No. 1735.0930001/RWE/BSA), that is disclosed and claimed in a patent application of the same title by the inventors (1) Sui Xiong CAI, (2) Azra PERVIN, (3) Shailaja KASIBHATLA and (4) Bao Ngoc NGUYEN (said application has a 371(c) Date of March 21, 2006, at the U.S. Patent and Trademark Office, and having Application Number 10/572,910, which is the U.S. national phase of International Application No. PCT/US2004/032570, International Filing Date October 5, 2004).

For the purpose of PAIR, the Customer Number is 26111.

The Assignee hereby appoints the patent practitioners associated with CUSTOMER NUMBER 26111 to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith. The Assignee hereby grants said patent practitioners associated with CUSTOMER NUMBER 26111 the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

CUSTOMER NUMBER 26111

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. 1100 New York Avenue, N.W. Washington, D.C. 20005-3934 U.S.A.

Direct phone calls to 202-371-2600.

FOR: Cytovia, Inc

SIGNATURE: Sen Texp

BY: BEN TSENG

TITLE: VP Research

DATE: 19 line 2007

622139 1.DOC